Videos

Sara Hurvitz, MD, provides insight on the potential role of amcenestrant in the treatment of HR+ breast cancer in the future.

An expert in breast oncology shares her thoughts on the importance of the AMEERA-5 findings to the evolving treatment landscape for HR+ breast cancer.

Sara Hurvitz, MD, reviews clinical trial data on amcenestrant, an orally administered endocrine therapy, in patients with ER+/HER2- breast cancer as shown in the AMEERA trials.

Sara Hurvitz, MD, discusses the therapeutic landscape for HR+ advanced breast cancer and considerations for treatment selection.

Sara Hurvitz, MD, provides an overview of HR+ breast cancer.

Neeraj Agarwal, MD, discusses the updated results of the phase 3 TITAN study, which analyzed the efficacy of apalutamide plus androgen deprivation therapy versus ADT plus placebo in patients with metastatic hormone-sensitive prostate cancer.

Robert J. Motzer, MD, shares his insights on the future of treatment for advanced renal cell carcinoma.

Dr Motzer discusses data from the CLEAR trial that were presented at ASCO 2021.

An expert explains the impact of the CLEAR trial on clinical practice and reviews NCCN guidelines for the management of advanced renal cell carcinoma.

Dr Robert J. Motzer introduces data from the phase 3 CLEAR trial, which investigated lenvatinib plus pembrolizumab or everolimus for the treatment of advanced renal cell carcinoma.

Robert J. Motzer, MD, gives a background on the current first-line therapy options for advanced renal cell carcinoma, including challenges and unmet needs.

Mounzer Agha, MD, discusses the phase 2 CARTITUDE-2 trial looking at ciltacabtagene autoleucel in patients with multiple myeloma.

Jyoti Malhotra, MD, MPH, discusses the preliminary efficacy signals of the combination therapy plinabulin, nivolumab, and ipilimumab in patients with relapsed/refractory small cell lung cancer.

Hope Rugo, MD, provides insights on best practices for managing metastatic TNBC in community settings.

An expert explains the different types of immune-related adverse effects associated with the use of immune checkpoint inhibitors.

Lori Wirth, MD, discusses unmet needs and future considerations in the management of differentiated thyroid cancer.

Lori Wirth, MD, reviews key efficacy data from the post hoc analysis of the SELECT trial investigating the use of lenvatinib in patients with lung metastases.

Dr Hope Rugo discusses the importance of testing for germline BRCA1/2 mutations in patients with triple-negative breast cancer.

Hope Rugo, MD, continues to discuss key clinical trials affecting metastatic triple-negative breast cancer, including IMpassion131.

An overview of how SELECT trial data affected clinical treatment practice for patients with differentiated thyroid cancer.

Medical oncologist Lori Wirth, MD, discusses treatment options for patients with radioiodine-refractory metastatic disease.

An expert in breast oncology discusses the IMpassion130 and KEYNOTE-355 clinical trials.

Dr Rugo educates on early stage treatment options and molecular testing guidelines for patients with metastatic triple-negative breast cancer.

Lori Wirth, MD, discusses treatment options and potential adverse effects for differentiated thyroid cancer.

Lori Wirth, MD, provides an overview and diagnosis consideration of differentiated thyroid cancer and its related subtypes.

Hope Rugo, MD, discusses the case of a 49-year-old woman diagnosed with metastatic triple-negative breast cancer.

A thought leader in hematology oncology highlights therapies currently in development for the management of CLL and provides closing remarks on unmet needs regarding patients who are double-refractory.

Jeff Sharman, MD, shares insight into best practices for monitoring and managing adverse effects of treatment in chronic lymphocytic leukemia including elevated liver function tests, diarrhea, and pneumocystis pneumonia.

An expert in the management of chronic lymphocytic leukemia discusses how patient- and disease-related factors influence treatment decisions after relapse.

A key opinion leader in hematology oncology provides an overview of treatment options for patients with newly diagnosed CLL and discusses factors to consider when monitoring patients for disease relapse.